Lepodisiran Sodium

Approval Year

Substance Class	Nucleic Acid Created by `admin` on `Sat Dec 16 18:33:25 GMT 2023` Edited by `admin` on `Sat Dec 16 18:33:25 GMT 2023`
Nucleic Acid Type	siRNA
Nucleic Acid Subtype
Sequence Origin	SYNTHETIC
Sequence Type	COMPLETE
Record UNII	7DR6F86F5U
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Lepodisiran Sodium

Official Name

English

LY-3819469 SODIUM

Code

English

RNA, ([4′-de(hydroxymethyl)-4′-[(hydroxymethoxyphosphinyl)methoxy]]Um-sp-(2′-deoxy-2′-fluoro)A-sp-(2′-deoxy-2′-fluoro)G-sp-(2′-deoxy-2′-fluoro)A-(2′-deoxy-2′-fluoro)U-Gm-(2′-deoxy-2′-fluoro)A-Cm-Cm-(2′-deoxy-2′-fluoro)A-Am-Gm-

Common Name

English

LY3819469 SODIUM

Code

English

LEPODISIRAN SODIUM [USAN]

Common Name

English

duplex of all-P-ambo-4′-de(hydroxymethyl)-4′-[(hydroxymethylphosphinoyl)methoxy]-2′-O-methylthiouridylyl-2′-deoxy-2′-fluorothioadenylyl-(3'→5')-2′-deoxy-2′-fluorothioguanylyl-(3'→5')-2′-deoxy-2′-fluoroadenylyl-(3'→5')-2′-deoxy-

Common Name

English

Code System Code Type Description

CAS

2766131-24-0

Created by admin on Sat Dec 16 18:33:25 GMT 2023 , Edited by admin on Sat Dec 16 18:33:25 GMT 2023

PRIMARY

USAN

LM-87

Created by admin on Sat Dec 16 18:33:25 GMT 2023 , Edited by admin on Sat Dec 16 18:33:25 GMT 2023

PRIMARY

FDA UNII

7DR6F86F5U

Created by admin on Sat Dec 16 18:33:25 GMT 2023 , Edited by admin on Sat Dec 16 18:33:25 GMT 2023

PRIMARY

Sugar	Site Range	Site Count
2'-Fluoro-Ribose	1_8-1_11;2_2-2_5;2_7;2_10;2_14	11 / 58
2'-O-Methyl-Ribose	1_1-1_7;1_12-1_36;2_1;2_6;2_8-2_9;2_11-2_13;2_15-2_22	47 / 58

Linkage	Site Range	Site Count
	1_3-1_36;2_5-2_20	50 / 56
Sodium Phosporothioate	1_2;2_2-2_4;2_21-2_22	6 / 56

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
NUCLEOSIDE_SUBSTITUTION	[1_28] [1_29] [1_30]	SITE_SPECIFIC			UNSPECIFIED SUBSTANCE	3a625511 (not in database)
NUCLEOTIDE SUBSTITUTION	[2_1]	3'-TERMINUS			UNSPECIFIED SUBSTANCE	b6cbe77c (not in database)